Bifogade filer
ProstaLund AB (publ) Interim Report January September 2023
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
1 July - 30 September 2023
· Net sales reached SEK 4,8 (3,8) million.
· Loss after taxes SEK -6,2 (-2,1) million
· Earnings per share were SEK -0,08 (-0,04)
· Cash and equivalents were 22,9 (15,9) million
Significant events during the period
· The company decided to withdraw the 510(k) application in the USA for the Schelin Catheter®
· The company decided to instead apply for approval in the USA via the De Novo process for the Schelin Catheter®
· Patent was approved in China
· Sales started in Austria
· Agreement with sales agent in France was signed
· The CEO and management team resigned at their own request
· Board member Mats Alyhr resigned at his own request
· Executives reported the chairman of the board Lars Johansson and resigning board member Mats Alyhr to the police
· The board dismissed the outgoing CEO and appointed Micael Karlsson, Advokatfirman Delphi as interim CEO
1 January - 30 September 2023
· Net sales reached SEK 15,8 (11,9) million
· Loss after taxes SEK -13,6 (-8,0) million
· Earnings per share were SEK -0,21 (-0,15)
Significant events after the period
· Extraordinary general meeting – New election of Per Langö, Tomas Eriksson, Paul de Potocki and Tom Rönnlund as regular board members and re-election of Marianne Östlund and Annette Colin as regular board members
· Per Langö elected as chairman of the board
· Anders Kristensson appointed as new CEO
| Key figures | |||
| (SEK MILLION) | Jan-Sep 2023 | Jan-Sep 2022 | Jan-Sep 2021 |
| Net sales | 15,8 | 11,9 | 12,1 |
| Gross margin % | 69,3 | 76,7 | 85,4 |
| Operating profit/loss | -13,6 | -7,7 | -5,6 |
| Cash flow from operating activities | -18,2 | -13,0 | -6,3 |
| Average number of employees | 9 | 7 | 7 |
“With world-class products, we aim to improve the everyday life and future of men with prostate problems”.
Anders Kristensson
CEO, ProstaLund AB (publ)
For further questions, please contact
Anders Kristensson, CEO of ProstaLund AB (publ)
E-mail: anders.kristensson@prostalund.com
Certified Adviser:
Västra Hamnen Corporate Finance AB
Telephone: +46 40 200 250
E-mail: ca@vhcorp.se
About ProstaLund
ProstaLund AB is a Swedish medical technology company with headquarters in Lund that develops and markets innovative products for the treatment of benign prostate enlargement. The company has patented the treatment method CoreTherm, a personalised heat treatment for BPH (benign prostatic hyperplasia). ProstaLund is listed on Nasdaq First North Growth Market and has approximately 4,000 shareholders. See also - www.prostalund.se. Our press releases are also available to read and download here: www.prostalund.se/pressmeddelanden.